Aims Single dose pharmacokinetics and safety of irbesartan, an angiotensin II receptor antagonist, were evaluated in healthy young and elderly male and female subjects. Methods Irbesartan was administered as two 25 mg capsules after a 10 h fast to 12 young men, 12 young women, 12 elderly men and 12 elderly women. Serial blood and urine sample were collected up to 96 h after the dose. Plasma and urine samples were analysed for irbesartan by h.p.l.c./fluorescence methods. Results No statistically significant gender effects were observed in peak plasma concentration (C max ), area under the curve (AUC), and terminal elimination halflife (t 1/2 ) of irbesartan. The geometric mean AUC and C max increased by about 43% and 49%, respectively, in the elderly subjects. Also the time to peak was significantly shorter in the elderly subjects compared with that observed in the young subjects. Renal clearance of irbesartan was significantly reduced in the elderly females but this reduction is not likely to be of any clinical relevance since less than 3% of the administered dose of irbesartan is excreted unchanged in the urine. Conclusions Although there was an effect of age on the pharmacokinetics of irbesartan, based on the safety and efficacy profile, no adjustment in irbesartan dosage is necessary with respect to age or gender.
Introduction young females were 61 (9.8) and 31 (6.8), respectively. Corresponding values for elderly males were 71 (9.5) and The recent development of several imidazole angiotensin II receptor antagonists offers several advantages over ACE 72 (3.5) and those for elderly females were 61 (9.8) and 69 (4.3), respectively. inhibitors in the treatment of hypertension [1] [2] [3] . Irbesartan, is a potent, long-acting angiotensin II receptor antagonist (AT 1 subtype) [4] that effectively decreases blood pressure in a doseStudy design dependent manner in patients with mild-to-moderate hypertension [5, 6] 
and exhibits linear kinetics over the therapeutic
This was an open-label, single dose, parallel group design. The study protocol was approved by the Institution Review dose range [7] . The principal objective of the study was to assess the effects of age and gender on the single dose Board of the Besselaar Clinical Research Units, West Palm Beach, FL. Each subject received a single 50 mg dose pharmacokinetics of irbesartan.
(2×25 mg capsules) of irbesartan with 250 ml water after an overnight (#10 h) fast. The subjects continued to fast Methods for 4 h after administration. Serial blood and urine samples were collected for 96 h after administration for analysis of Subjects unchanged irbesartan. Vital sign measurements were taken during the entire study; clinical laboratory tests and physical A total of 48 healthy subjects participated in the study after giving a written informed consent. The criteria for selecting examinations were also performed to monitor subjects' safety. subjects were no history or evidence of heart disease, renal or hepatic disease, pulmonary obstructive disease, bronchial asthma or hypertension. Subjects with a history of drug or
Sample collection and handling alcohol use were excluded from the study. Pregnant, nursing women or those using oral contraceptive drugs were not Approximately 10 ml blood was collected into VacutainersA (Becton and Dickinson, Rutherford, NJ) containing tripotasincluded in the study. Subjects with blood pressure <90/60 mmHg or>140/100 mmHg, or pulse rates <50 sium ethylenediamine tetraacetic acid (K 3 EDTA) as an anticoagulant. Blood samples were collected before and at beats min −1 or>90 beats min −1 were also excluded. The mean (s.d.) body weight (kg ) and age (years) of young 0. 33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 30, 36, 48, 60, 72, 84 , and 96 h after dose administration. The plasma was tube and stored at or below −20°C until analysis.
Urine samples were collected over the following specified parameters of irbesartan (C max , AUC, t max , t 1/2 , %UR and CL R ) were evaluated using an analysis of variance (anova). time intervals: predose, and 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-60, 60-72 and 72-96 h after administration.
The analysis included factors for age, gender, and age-by-gender interaction. A priori, the variables C max , and AUC were log Each urine sample consisted of the total urine voided over the specified collection interval. At the end of each interval, transformed and t max was rank transformed. All tests of statistical hypotheses were carried out at the two-tailed 5% significance a 5 ml aliquot was transferred to a prelabeled storage tube and frozen at or below −20°C until analysis.
level and all interval estimates are two-sided and constructed with 95% confidence intervals.
Sample assay methods
Plasma and urine samples were analysed fro irbesartan by a Results validated h.p.l.c./fluorescence procedure [8] . The lower limit of quantification (LLQ) was established at 1 ng ml −1 . Safety The standard curve range was 1-1000 ng ml −1 for plasma No clinically significant abnormalities or changes in vital and 1-500 ng ml −1 for urine. Plasma and urine quality signs were observed after receiving irbesartan. A total of 19 control (QC) samples were prepared before the study began episodes of adverse events were reported by 13 subjects (i.e. and stored along with the study samples. The overall within-27% of the total subjects). The most frequently reported and between-run precision for the plasma and urine QCs adverse event was headache. A total of six subjects reported was less than 6% and 10% relative standard deviation, headache. The second most commonly reported adverse respectively. The mean predicted concentrations of the event was muscular/skeletal pain, reported by 6% of subjects. plasma and urine QC samples deviated by less than 5% and
Other events reported were dizziness, somnolence, pharyn-3% from the nominal concentrations, respectively. gitis, and upper respiratory infection (2% of the total subjects per event). The investigator judged all the adverse events to Pharmacokinetic analyses be mild in terms of severity. The plasma concentration vs time data were analysed by using noncompartmental pharmacokinetic methods [9, 10] . The area under the plasma concentration-time curve (AUC) was
Pharmacokinetics of irbesartan calculated using a combination of the linear and log-trapezoidal
The mean plasma concentration vs time profiles are depicted rules. The AUC was extrapolated to infinity and expressed as in Figure 1 . Mean (s.d.) pharmacokinetic parameters for AUC. The highest observed concentration and the correspondirbesartan are summarized in Table 1 . No statistically significant ing sampling time were defined as C max and t max , respectively. gender effects, in either young or elderly subjects, were The terminal elimination half-life (t 1/2 ) was determined from observed for AUC, C max , t max , and t 1/2 of irbesartan. The the regression line that best fit the terminal portion of the mean AUC and C max were significantly (P≤0.001) greater in concentration-time curve. Renal clearance (CL R ) was calcuelderly subjects. The geometric mean AUC and C max were lated as the ratio of amount excreted in urine divided by the about 43% and 49% greater, respectively, in elderly subjects. AUC up to the same time point. Percent of dose in urine The median t max value was significantly (P=0.001) shorter in (%UR) was calculated as the cumulative amount (mg) in urine the elderly subjects. The t 1/2 values were not influenced by divided by the dose of irbesartan. age or gender. For variables percentage UR and CL R , considerable age-by-gender interactions were observed. For Statistical methods CL R , a statistically significant age effect was observed only in females. There was about a 56% reduction in the mean CL R Statistical analyses were carried out using SAS/STATA software version 6.07 (SAS Institute, Cary, NC). The pharmacokinetic in the elderly females compared with the young females. The confidence intervals to evaluate gender effect were calculated after pooling the data by age groups and that for age effect by pooling the data by gender.
Short report
patients with mild-to-moderate hypertension receiving either placebo or irbesartan (1 mg to 300 mg ) have clearly shown that the reductions from baseline in trough blood pressure were of similar magnitude for the subgroups of gender and age [15] . Irbesartan demonstrated an excellent tolerability profile with no evidence of dose-related toxicity in these two studies. Therefore, based on the safety and efficacy profile of irbesartan, no adjustment in irbesartan dosage is necessary with respect to age or gender.
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